Legacy Wealth Asset Management LLC Has $373,000 Holdings in Penumbra, Inc. (NYSE:PEN)

Legacy Wealth Asset Management LLC trimmed its stake in Penumbra, Inc. (NYSE:PEN) by 9.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,569 shares of the company’s stock after selling 162 shares during the period. Legacy Wealth Asset Management LLC’s holdings in Penumbra were worth $373,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp grew its position in Penumbra by 0.3% during the third quarter. State Street Corp now owns 1,236,671 shares of the company’s stock worth $240,298,000 after buying an additional 3,863 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Penumbra in the 2nd quarter valued at approximately $17,943,000. Thrivent Financial for Lutherans lifted its position in shares of Penumbra by 3,832.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company’s stock worth $71,564,000 after acquiring an additional 358,932 shares during the period. Vontobel Holding Ltd. acquired a new stake in shares of Penumbra during the 3rd quarter worth approximately $1,092,000. Finally, AlphaCentric Advisors LLC bought a new stake in shares of Penumbra during the third quarter valued at approximately $777,000. Institutional investors own 88.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Citigroup lifted their price target on shares of Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Robert W. Baird lifted their target price on shares of Penumbra from $244.00 to $248.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. BTIG Research upped their target price on shares of Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a report on Thursday, October 31st. Finally, Canaccord Genuity Group increased their target price on Penumbra from $260.00 to $323.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $258.00.

Penumbra Stock Up 0.7 %

Shares of NYSE PEN opened at $264.08 on Friday. Penumbra, Inc. has a 12-month low of $148.00 and a 12-month high of $277.34. The company has a market cap of $10.14 billion, a price-to-earnings ratio of 307.07, a price-to-earnings-growth ratio of 1.84 and a beta of 0.52. The company has a quick ratio of 3.25, a current ratio of 5.82 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $244.55 and its 200 day simple moving average is $212.47.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.16. Penumbra had a return on equity of 8.99% and a net margin of 2.97%. The business had revenue of $301.04 million for the quarter, compared to analysts’ expectations of $297.36 million. During the same quarter last year, the business earned $0.67 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. On average, research analysts expect that Penumbra, Inc. will post 2.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Penumbra news, CAO Lambert Shiu sold 1,798 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $242.56, for a total value of $436,122.88. Following the completion of the transaction, the chief accounting officer now directly owns 20,682 shares of the company’s stock, valued at approximately $5,016,625.92. The trade was a 8.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Adam Elsesser sold 15,000 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $204.56, for a total value of $3,068,400.00. Following the sale, the chief executive officer now directly owns 867,582 shares in the company, valued at approximately $177,472,573.92. This represents a 1.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,819 shares of company stock valued at $11,197,883 over the last ninety days. Insiders own 5.00% of the company’s stock.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.